1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Biocartis Group N.V.

Biocartis Group N.V.

BIOGF
Biocartis Group N.V.US flagOther OTC
0.66
USD
-3.84
- -
65.41MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
Revenue per Share
0.07
0.18
0.18
0.31
0.25
0.4
0.46
0.57
0.65
0.84
0.95
Basic EPS, GAAP
-0.94
-0.75
-0.19
-0.92
-1.03
-0.79
-0.8
-0.97
-0.95
-1.24
-1.08
Free Cash Flow per Basic Share
-1.03
-0.95
-0.81
-0.76
-1.34
-0.86
-0.8
-0.86
-0.64
-1.21
-0.77
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.3
-3.05
-3.11
-9.41
-9.54
-9.46
-9.15
-9.32
-10.18
-12.98
-10.96
Tangible Book Value per Share
0.56
0.46
0.22
2.44
1.81
2.3
1.35
1.19
0.47
-0.68
-0.58
Basic Weighted Avg Shares
47
47
47
43
48
53
60
66
66
58
61
Sales/Revenue/Turnover
4
8
8
13
12
21
28
37
43
48
57
Operating Margin (%)
-1,008.14
-316.46
-344.1
-297.43
-414.7
-207.99
-168.28
-147.81
-107.54
-129.06
-81.33
Depreciation Expense
3
4
5
5
5
5
4
10
10
10
10
Net Income, GAAP
-44
-36
-9
-40
-50
-42
-48
-64
-63
-71
-65
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,251.23
-427.46
-107.55
-298.48
-411.45
-200.22
-173.14
-171.1
-145.92
-148.07
-113.74
Working Capital
33
27
15
90
85
117
71
191
131
61
27
LT Debt
10
13
9
3
28
31
30
160
144
142
102
Total Equity
37
32
20
115
97
132
87
84
37
-34
-30
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.14%
-59.27%
-10.66%
Free Cash Flow
5.88%
5.88%
-32.65%
Net Income, GAAP
30.27%
10.22%
-8.52%
Sales/Revenue/Turnover
37.12%
22.71%
19.08%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
48
2022
- -
- -
- -
- -
57
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
-1.24
2022
- -
- -
- -
- -
-1.08
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Roger Moody
Full Time Employees
526
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Generaal de Wittelaan 11 B Mechelen Belgium 2800
IPO Date
Oct 14, 2021
Website
biocartis.com
Similar Companies
Stella Diagnostics Inc. (SLDX)
Tecan Group AG (0QLN.L)
Devyser Diagnostics AB (publ) (DVYSR.ST)
Tecan Group AG (TECN.SW)
Krsnaa Diagnostics Limited (KRSNAA.BO)
Prenetics Global Limited (PRENW)
Business
Biocartis Group NV (BIOGF) operates as a holding company following the enforcement action by secured creditors on October 31, 2023, which transferred all shares in its former operating subsidiaries to a new privately held entity owned by those creditors; prior to this restructuring, the company develops and commercializes innovative molecular diagnostics solutions focused on oncology through its proprietary Idylla platform, a fully automated real-time PCR-based system that delivers rapid, actionable results from routine tissue samples. The Idylla platform supports a comprehensive portfolio of cartridge-based assays, including oncology tests such as GeneFusion Panel, EGFR Mutation Test, BRAF Mutation Test, KRAS Mutation Test, NRAS-BRAF Mutation Test, MSI Test, Idylla Hepatopredict, ColonoDETECT, and the Merlin Assay; infectious disease tests addressing key pathogens; and oncology research assays for advanced biomarker analysis. Biocartis targets clinical laboratories, pharmaceutical companies, and healthcare providers worldwide, with primary operations in Europe including Belgium and extensions to the United States. The company maintains longstanding strategic collaborations, such as with Amgen for Idylla RAS testing to enable decentralized oncology diagnostics and with Bristol-Myers Squibb for MSI testing in immuno-oncology applications; additional partnerships include agreements with GeneproDx for ThyroidPrint genomic testing and APIS Assay Technologies for breast cancer subtyping assays on the Idylla platform. Founded in 2007 and headquartered at Generaal De Wittelaan 11B, 2800 Mechelen, Belgium, Biocartis Group NV lists on Euronext Brussels under ticker BCART and continues to disclose financials, including its 2023 annual report and August 2025 annual general meeting proceedings.